In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Pulmotect, Inc.

https://pulmotect.com/

Latest From Pulmotect, Inc.

Pulmotect Seeks Quick-To-Market Path For Rapid-Acting Respiratory Drug

Selected by NIH and NSF for the Innovation Zone at BIO 2017, the Houston biotech's synthetic broad-spectrum drug has shown activity in animal models against every pathogen tested. Pulmotect hopes PUL-042 can prevent exacerbations in COPD patients who develop upper respiratory infections.

Respiratory Infectious Diseases

Pulmotect Inc.

Pulmotect Inc. is developing a synthetic inhaled drug to prevent pneumonia in cancer patients. Its lead candidate PUL-042 is a broad-spectrum, immune stimulant with a unique formulation that targets the epithelial cells that line the airways.

BioPharmaceutical

Start-Up Previews, December 2015

In this month's issue of Start-Up, we profile Flow Forward, Intensity Therapeutics, Perimeter Medical Imaging, PhageTech and Pulmotect.

Medical Device BioPharmaceutical

Recent Dealmaking (02/2004)

Summarizing the month in European dealmaking.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register